Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients

Journal of Clinical Oncology

Volumn 24, Issue 31, 2006, Pages 4998-5004

  Van Geelen, Caroline M ^a   Westra, Jantine L ^a   De Vries, Elisabeth G ^a   Boersma Van Ek, Wytske ^a   Zwart, Nynke ^a   Hollema, Harry ^a   Boezen, H Marike ^a   Mulder, Nanno H ^a   Plukker, John T ^a   De Jong, Steven ^a   Kleibeuker, Jan H ^a   Koornstra, Jan J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; MEMBRANE PROTEIN; TNFRSF10A PROTEIN, HUMAN; TNFRSF10B PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; ADULT; AGED; CHEMISTRY; COLON TUMOR; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; MALE; MIDDLE AGED; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK; SURVIVAL; UPREGULATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SURVIVAL ANALYSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 33750958561     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.8809     Document Type: Article

References (52)

1. Gramont A: Adjuvant therapy of stage II and III colon cancer. Semin Oncol 32:11-14, 2005 (suppl)
2. Lowe SW, Ruley HE, Jacks T, et al: P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
3. Lowe SW, Bodis S, McClatchey A, et al: P53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
4. Ravi R, Jain AJ, Schulick RD, et al: Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 64:9105-9114, 2004
5. Westra JL, Schaapveld M, Hollema H, et al: Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 23:5635-5643, 2005
6. S. Pitti RM, Marsters SA, Ruppert S, et al: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690, 1996
7. Wiley SR, Schooley K, Smolak PJ, et al: identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682, 1995
8. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162, 1999
9. Kelley SK, Harris LA, Xie D, et al: Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31-38, 2001
10. Lawrence D, Shahrokh Z, Marsters S, et al: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385, 2001
11. Mitsiades CS, Treon SP, Mitsiades N, et al: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications. Blood 98:795-804, 2001
12. Nagane M, Pan G, Weddle JJ, et al: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60:847-853, 2000
13. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163, 1999 14. Held J, Schulze-Osthoff K: Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat 4:243-252, 2001
14. Hengartner MO: The biochemistry of apoptosis. Nature 407:770-776, 2000
15. Reed JC: Mechanisms of apoptosis. Am J Pathol 157:1415-1430, 2000
16. Koornstra JJ, Kleibeuker JH, van Geelen CM, et al: Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 200: 327-335, 2003
17. Sträter J, Hinz U, Walczak H, et al: Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 8:3734-3740, 2002
18. Wang S, El-Deiry WS: Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 64:6666-6672, 2004
19. Tran SE, Holmstrom TH, Ahonen M, et al: MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 276: 16484-16490, 2001
20. Malhi H, Gores GJ: TRAIL resistance results in cancer progerssion: A TRAIL to perdition? Oncogene [Epub ahead of print June 5, 2006]
21. Baader E, Tolocko A, Fuchs U, et al: Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res 65:7888-7895, 2005
22. Bleeker WA, Mulder NH, Hermans J, et al: The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer: IKN Colon Trial Group. Ann Oncol 11:547-552, 2000
23. Hamilton SR, Aaltonen LA (ed). WHO Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Geneva, Switzerland, World Health Organization, 2000
24. Greene FL, Stewart AK, Norton HJ: A new TNM staging strategy for node-positive (stage III) colon cancer: An analysis of 50,042 patients. Ann Surg 236:416-421, 2002
25. Westra JL, Hollema H, Schaapveld M, et al: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 16:1646-1653, 2005
26. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005
27. Takimoto R, El-Deiry WS: Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19: 1735-1743, 2000
28. Liu X, Yue P, Khuri FR, et al: p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 64:5078-5083, 2004
29. Hayes DF, Bast RC, Desch CE, et al: Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466 1996
30. Ishimura N, Isomoto H, Bronk SF, et al: Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290:G129-G136, 2006
31. Trauzold A, Siegmund D, Schniewind B, et al: TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene [Epub ahead of print June 5, 2006]
32. Truneh A, Sharma S, Silverman C, et al: Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 275:23319-23325, 2000
33. Kelley RF, Totpal K, Lindstrom SH, et al: Receptor-selective mutants of Apo2L/TRAIL reveal a greater contribution of DR5 than DR4 to apoptosis signaling. J Biol Chem 280:2205-2212, 2005
34. Dechant MJ, Fellenberg J, Scheuerpflug CG, et al: Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer 109:661-667, 2004
35. Fisher MJ, Virmani AK, Wu L, et al: Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 7:1688-1697, 2001
36. Lancaster JM, Sayer R, Blanchette C, et al: High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res 9:762-766, 2003
37. Arts HJ, de Jong S, Hollema H, et al: Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol 92:794-800, 2004
38. Min YJ, Lee JH, Choi SJ, et al: Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia. Leuk Res 28:359-365, 2004
39. Spierings DC, de Vries EG, Timens W, et al: Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9:3397-3405, 2003
40. McCarthy MM, Sznol M, DiVito KA, et al: Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 11:5188-5194, 2005
41. Bubendorf L, Nocito A, Moch H, et al: Tissue microarray (TMA) technology: Minitiaturized pathology archives for high-throughput in situ studies. J Pathol 195:72-79, 2001
42. Koornstra JJ, Jalving M, Rijcken FE, et al: Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: Potential targets for apoptosis induction. Eur J Cancer 41: 1195-1202, 2005
43. Pukac L, Kanakaraj Humphreys R, et al: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92:1430-1441, 2005
44. Motoki K, Mori E, Matsumoto A, et al: Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 11:3126-3135, 2005
45. Mita M, Tolcher AW, Patnaik A, et al: A phase 1, pharmacokinetic (PK) study of HGS-ETR1, an agonistic monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors. Proc Am Assoc Cancer Res, 2005 (abstr 544)
46. Tolcher, Wakelee H, Mita M, et al: A Phase 1 clinical trial HGS-ETR2, a fully human monoclonal antibody to TRAIL-R2 in patients with advanced solid tumors. Proc Am Assoc Cancer Res, 2005 (abstr 543)
47. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62:5800-5806, 2002
48. van Geelen CM, de Vries EG, Le TK, et al: Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer 89:363-373, 2003
49. He Q, Huang Y, Sheikh MS: Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 23: 2554-2558, 2004
50. Kim YH, Park JW, Lee JY, et al: Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 25:1813-1820, 2004
51. LeBlanc H, Lawrence D, Varfolomeev E, et al: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8:274-281, 2002
52. Shimoyama S, Mochizuki Y, Kusada O, et al: Supra-additive antitumor activity of 5FU with tumpr necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. Int J Oncol 21: 643-648, 2002